Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Oncology > Colorectal Ca > Flashcards

Colorectal Ca Flashcards

1
Q

What is the most common cancer overall in Au?

A

pancreas then bowel then breast

mortality number 1 is lung

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the risk per year of colon cancer in IBD?

A

1% per year after 8 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What impact does calcium and vitamin D have on colon cancer risk?

A

Modest but definite benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the characteristics of a HNPCC cancer?

A

Often right sided, mucinous, poorly differentiated, inflammatory infiltrate, multiple primaries common

Early tumours have better prognosis than MSS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How has the testing for microsatellite instability been stabilised?

A

Check for five different repeats (three dinucleotide and two mononucleotide) MSI if over 40 percent, meaning 2 or more of the 5 marker panel. This is according to the Bethesda criteria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do you actually check for deficient mismatch repair in someone with cancer?

A

Microsatellite instability testing on tumour via PCR
Immunohistochemistry- look for LOSS of staining of MSH2 nd MLH1 or MSH 6

There is a 95% concordance between IHC and MSI- first is cheaper and easier. Need to go on to sequence after IHC if want to define the specific mutation and permit family screening.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What impact does FOBT testing have on patient outcomes?

A

Reduce mortality by 20%
In Au FOBT offerred at 50,55,60,65,70,74
Detect more at earlier stage (ie A)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

In NEJM article, if you do multitarget stool DNA testing for colorectal cancer screening, how does it differ?

A

More advanced R sided lesions detected

Increased sensitivity, decreased specificity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is lead time bias?

A

Screening data looks like patients have prolonged survival but they are just more likely to be diagnosed at earlier, asymptomatic stage and then live just as long

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is length time bias?

A

Slower growing, less aggressive tumours have longer asymptomatic phase where screening can detect compared with fast growing dangerous tumours- this makes it look like the screen detected patients have better outcomes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What imaging should be done in rectal cancers now?

A

MRI to assess local extent (previously endorectal ultrasound)

MERCURY study showed correlation between rectal MRI and the histopathology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What chemo is given for stage 3 colorectal ca

A

Oxaliplatin + 5FU + leucovorin

Note that in high risk stage II cancers, would also consider administering

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the chemo in advanced bowel ca?

A

Folfox = lukovorin +5FU + oxaliplatin
or
Folfiri = leukovorin +5FU + irinotecan

Sometimes combined with a biologic (bevacizumab or cetuximab)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cancers associated with HNPCC

A 
Colorectal
Endometrial
Ovarian
Renal pelvis
Ureter
Small bowel

80% lifetime risk colorectal ca

Call the sporadic cancers and lynch cancers “MSI-hihg” if found to be deficient in MMR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cancers associated with FAP

A 
Colorectal
Desmoid
Small bowel
Pancreas
Papillary thyroid
Brian
Stomach
Hepatobiliary
Adrenal

95-100% lifetime risk colorectal Ca

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the two pathways to microsatellite instability?

A

Germline pathway with mutations in MMR genes–>MSI-H

Sporadic CRC via CIMP positive pathway) where there is hypermethylation of MLH1–>MSI-H

IN each case defective MMR causes an accumulation/variation of repeated DNA sequences called microsatelites–>frame shift mutations–>defective proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the criteria called for identifying if someone may have Lynch syndrome?

A 
Amsterdam criteria
Bethesda criteria (newer, more lenient)

Use to decide if patient warrants genetic testing (or immunohistochemistry then genetic testing) based on family history of cancers and age of onset.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What mutations do you look for in HNPCC

A

MLH1 and MSH2 are the most important

Also MSH6 and PMS2 or EPCAM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How should MSI-H colon cancer be treated differently (two points)?

A
  1. No benefit to adjuvant 5FU

2. Evidence for aspirin as secondary prevention in the CAPP2 trial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

TNM colon ca 5 year survivials

A

I- 90-95%
II- 70-85%
III - 25-70%
IV- 0-10%

21
Q

What are the histopathological risk factors for recurrence?

A 
T4
Tumour perforation
Number involved LN
Extramural vascular invasion
Inadequate LN sampling
Mucinous
22
Q

What effect does preoperative radiation therapy have where there is curative intent?

A

Does not improve survival but does improve local recurrence rates

23
Q

What is the best timing for radiotherapy? Before? After surgery?

A

Pre-op radiotherapy has a reduction in risk of local recurrence but disease free and overall survival remain the same.

24
Q

Mechanism of bevacizumab

A

Blocks VEGF pathway by binding to the ligand before it can bind to the VEGF receptor

25
Q

Ramucirumab

A

Blocks VEGF pathway by binding to the VEGF2 receptor

26
Q

Cetuximab and Panitumumab…MOA?

A

Binds EGFR receptor

27
Q

Why check for kras mutation in colorectal ca?

A

If wild type, may benefit from cetuximab
If mutated KRAS, constitutively active pathway, so blocking of receptor at cell surface via Cetuximab will have no effect

28
Q

Side effects of Bevacizumab

A 
GI perforation
Bleeding
Thrombosis
Proteinuria
Delayed wound healing
Reversible posterior leukoencephalopathy syndrome
29
Q

Side effects of Cetuximab

A

Acneiform rash - worse rash correlates with better disease response
Hypomagnesaemia
Diarrhoea

If just a mild rash, evidence that can escalate dose and no worries!

30
Q

What is Regorafenib and how does it work?

A

Regorafenib is a protein kinase inhibitor with a similar structure to sorafenib. It is thought to work by inhibiting multiple signalling pathways involved in angiogenesis and tumour growth.

Final line after been through all chemos in metastatic colorectal Ca

31
Q

When do you actually use Bevacizumab in colon cancer?

A

In metastatic colon cancer in combination with standard first line chemotherapy

You don’t use it in resectable disease

32
Q

When do you actually use Cetuximab in colon cancer?

A

Metastatic colon cancer, not resectable disease

Also used in head and neck squamous cell ca

33
Q

Has PET been validated pre-op in colorectal ca?

A

No

34
Q

Should pre-op chemoradiotherapy be given in recal ca? What about post op?

A

Stage II or III should have pre-op 5-FU and radiotherapy (ie if any lymph nodes or it is a full thickness tumour). If thought to be stage I and then post op found to have LN involvement, get post op chemoradiation.

FOLFOX given post chemoradio to complete 6 months total

35
Q

What is the mechanism of giving leukovorin with 5-FU?

A

Causes 5-FU to bind tumour more effectively, but no intrinsic antitumour activity

36
Q

What about using anti-VEGF and anti-EGFR agents together?

A

Unexpected deleterious effect on outcomes

37
Q

What is the MAIN reason for doing surveillance colonoscopy post resection?

A

To look for new polyps which could become second primaries

To a much lesser extent to identify recurrent disease.
Local recurrence is FAR more common in rectal cancer than colon cancer patients.
Also more likely to have metachronous cancer if proximal to the splenic flexure

38
Q

Which type of FOBT should be used?

A

Two main types of FOBT are available: guaiac and faecal immunochemical tests.
Immunochemical tests are preferred as they have greater sensitivity and higher uptake.

39
Q

Colon cancer screening in Au? Who?

A

5 yearly FOBT from age 50 to 74

Medium risk get 5 yearly colonoscopy with intervening FOBT from age 50 or 10 years younger than youngest person in family to get cancer

40
Q

Who gets pap smears in au?

A

2 yearly age 18-70 if have been sexually active

41
Q

First line for colon cancer in a well person

A

add oxaliplatin to 5Fu- recurrence rates halved if can add the oxaliplatin

42
Q

pos FOBT- what chance cancer

A

5/10 normal colon
1/10 colon cancer
4/10 adenoma

43
Q

Characteristics of a MSI tumour

A 
more right sided
poorly differentiated
no point giving f-FU
more mucinous component
lymphocyte infiltration
44
Q

Aspirin and NSAIDS in familial CRC?

A

NSAIDS reduce polyps but not cancer in FAP

aspirin reduces cancer by 15% in HNPCC

45
Q

What are microsatelites

A

MMR proteins correct errors of DNA replication. If no correction then defective sequences called microsatellites develop–>frame shift mutation–>defective proteins

either from germline or sporadic as with hypermethylation of MLH-1 promoter region

46
Q

CEA pre op useful how

A

predicts recurrence

47
Q

What does radiation therapy achieve in stage 2 or 3?

A

reduce local recurrence

no effect on survival

48
Q

Why leukovorin with folfox

A

potentiates the 5-FU inhibition of thymidylate synthase

49
Q

MLH1 + PMS 2 lost
MSH 2 and 6 lost
MSH6 or PMS2 lost by themselves?

A

in either sporadic or hered
ONLY in HNPCC
only in HNPCC- rare

Oncology (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions